Recruiting
Acute myeloid leukaemia refractory+1
RecruitingStudy on the Safety of Eganelisib Alone and with Cytarabine for Patients with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
Registered drugNo placebo
Study on the Safety of Eganelisib Alone and with Cytarabine for Patients with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
Registered drugNo placebo
- Disease:Acute myeloid leukaemia refractoryAcute myeloid leukaemia recurrent
- Substances:CytarabineEganelisib
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Cytarabine
